Across TCGA pan-cancer cohorts, TSC22D2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TSC22D2 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TSC22D2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TSC22D2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where TSC22D2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.619	0.874	<.001	100	view →
HNSC	DFS	Tertile	All	0.806	0.518	.001	57	view →
PDAC	OS	Quartile	II,III,IV	0.342	0.597	.003	24	view →
GBM	DFS	Quartile	All	0.496	0.232	.007	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TSC22D2 tumor-vs-normal RNA expression · all TSC22D2 data types